Facultative hyperopia: It is the part of hyperopia corrected by patients accommodation. Absolute hyperopia: It is the residual part of hyperopia which causes blurring of vision for distance.So, Total hyperopia= latent hyperopia + manifest hyperopia (facultative + absolute)

Treatment
Corrective lenses
The simplest form of treatment for far-sightedness is the use of corrective lenses, i.e. eyeglasses or contact lenses. Eyeglasses used to correct far-sightedness have convex lenses. Surgery
There are also surgical treatments for far-sightedness:
Laser procedures

Photorefractive keratectomy (PRK): This is a refractive technique that is done by removal of a minimal amount of the corneal surface. Hyperopic PRK has many complications like regression effect, astigmatism due to epithelial healing, and corneal haze. Post operative epithelial healing time is also more for PRK. Laser assisted in situ keratomileusis (LASIK): Laser eye surgery to reshape the cornea, so that glasses or contact lenses are no longer needed. Excimer laser LASIK can correct hypermetropia up to +6 diopters. LASIK is contraindicated in patients with lupus and rheumatoid arthritis. Laser epithelial keratomileusis (LASEK): Resembles PRK, but uses alcohol to loosen the corneal surface. Epi-LASIK: Epi-LASIK is also used to correct hyperopia. In this procedure, use of epikeratome eliminates the use of alcohol. Laser thermal keratoplasty (LTK): Laser thermal keratoplasty is a laser based non-destructive refractive procedure used to correct hyperopia and presbyopia. It uses Thallium-Holmium-Chromium (THC): YAG laser.IOL implantation

Aphakia correction: High degree hypermetropia due to absence of lens (aphakia) is best corrected using intraocular lens implantation.
The authorized use includes treatment for those who are 65 years of age or older or who have certain chronic medical conditions. While bamlanivimab and etesevimab administered together resulted in a lower risk of resistant viruses developing during treatment compared with bamlanivimab administered alone, both treatments are available under an EUA and are expected to benefit people at high risk of disease progression. On 16 April 2021, the FDA revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. The EUA was issued to Eli Lilly and Co.In February 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started rolling reviews of data on the use of the monoclonal antibodies casirivimab/imdevimab, bamlanivimab/etesevimab, and bamlanivimab for the treatment of COVID-19. In March 2021, the CHMP concluded that bamlanivimab and etesevimab can be used together to treat confirmed COVID-19 in people who do not require supplemental oxygen and who are at high risk of their COVID-19 disease becoming severe. The CHMP also looked at the use of bamlanivimab alone and concluded that, despite uncertainties around the benefits of monotherapy, it can be considered a treatment option. In October 2021, the CHMP ended the rolling review of bamlanivimab/etesevimab. References
This article incorporates public domain material from the United States Department of Health and Human Services. External links
"Bamlanivimab". Drug Information Portal. U.S. National Library of Medicine. "Etesevimab". Drug Information Portal.